Nevertheless, our results suggest that the two sPLA2 inhibitors might be a valid therapeutic approach for FTLD-GRN, and possibly also other neurodegenerative diseases, to restrict neuroinflammation [62]. The gene discussed is GRN; the disease is neurodegenerative disease.